76X-93161-85438
2 vaccinations
5 coded responses
10 check-ins
5 free-text entries
0 call cases
- Sex
- —
- Age at first dose
- 41-45
- ZIP prefix
- 021 / MA
- Registered
- 2021-01-25
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-04
Dose 1 — Pfizer-BioNTech
-
2021-01-22
Dose 2 — Pfizer-BioNTech
-
2021-01-25
Registered in v-safe
-
2021-01-25
Survey response — days 1–6 daily, dose 2MedDRA: Lymphadenopathy — Feeling: Fair · Site: Pain, Redness · Headache, Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: About 36 hours after 2nd injection I developed very significant 10x7cm area of axillary swelling/adenopathy that was and is quite tender accompanied by parenthesis mostly in ulnar and medial cutaneous distributionMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-26
Survey response — days 1–6 daily, dose 2MedDRA: Lymphadenopathy — Feeling: Good · Site: Pain · Be unable to do your normal daily activitiesFree text: Continued significant ipsilateral axillary swelling/lymphadenopathyMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-27
Survey response — days 1–6 daily, dose 2MedDRA: Lymphadenopathy — Feeling: Good · HeadacheFree text: Continued significant ipsilateral axillary adenopathy though not worseMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-28
Survey response — days 1–6 daily, dose 2MedDRA: Lymphadenopathy — Feeling: Good · Fatigue or tirednessFree text: Continued ipsilateral axillary adenopathy though seems stable/not progressive and no more parestgesiasMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-29
Survey response — day 7, dose 2MedDRA: Lymphadenopathy — Feeling: GoodFree text: Continued ipsilateral axillary adenopathy though seems to be decreasingMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-02-05
- 2021-02-14
- 2021-02-21
- 2021-03-05
- 2021-04-24
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-04 | Pfizer-BioNTech | |
| 2 | 2021-01-22 | Pfizer-BioNTech |
Free text
Release 2 — days 1–6 daily, dose 2
Systemic reaction (other): About 36 hours after 2nd injection I developed very significant 10x7cm area of axillary swelling/adenopathy that was and is quite tender accompanied by parenthesis mostly in ulnar and medial cutaneous distribution
Systemic reaction (other): Continued significant ipsilateral axillary swelling/lymphadenopathy
Systemic reaction (other): Continued significant ipsilateral axillary adenopathy though not worse
Systemic reaction (other): Continued ipsilateral axillary adenopathy though seems stable/not progressive and no more parestgesias
Release 3 — day 7, dose 2
Systemic reaction (other): Continued ipsilateral axillary adenopathy though seems to be decreasing
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SRO | Lymphadenopathy | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release